Latest California Healthline Stories
The Food and Drug Administration allowed one company to send 50,000 reports of harm or malfunctions to an internal database even as patients worried about faulty defibrillators lodged in their hearts.
As part of his plan to tamp down drug pricing, President Donald Trump wants pharmaceutical companies to provide cost information in drug ads — just like side effects.
In the wake of a KHN investigation, the agency will no longer let device makers file reports of harm outside a widely used public database.
Critics are concerned about the explosion in controversial stem cell procedures offered by clinics — and, increasingly, respected hospitals.
With Scott Gottlieb making his exit from the Food and Drug Administration’s top spot, city and country health officials call for backup in the fight to curb teen use of e-cigarettes.
In the wake of a KHN investigation, Scott Gottlieb says releasing the records is in the public interest.
For almost two decades, device makers have sent reports of incidents to databases hidden from public view.
Only by the bizarre logic of the U.S. pharmaceutical industry does this drug count as any kind of generic.
In an interview, FDA Commissioner Scott Gottlieb reacts to a KHN/Fortune investigation of the drawbacks and risks of electronic health records.
Joanne Kenen of Politico, Anna Edney of Bloomberg News and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss the efforts to curb “surprise” medical bills to patients who inadvertently get out-of-network care; a look at where the 2020 presidential candidates stand on health; and the Trump administration’s efforts to end HIV in the U.S. Also, Rovner interviews Food and Drug Administration Commissioner Scott Gottlieb, who is leaving his job in early April.